Neurotrophins Market Size, Share, And COVID-19 Impact Analysis, By Type (Brain Derived Neurotrophic Factor, Nerve Growth Factor, Glial Cell Line-Derived Neurotrophic Factor, Ciliary Neurotrophic Factor, And Others), By Application (Alzheimer Disease, Parkinson Disease, Cancer, And Others), By End-User (Hospitals & Clinics, Diagnostic Centers, And Others), And Regional Forecast, 2024-2032

Neurotrophins are proteins comprising several neurotrophic factors that are known to support the survival of different classes of embryonic neurons. The neurotrophic factors are responsible for enhancing neuronal differentiation, inducing proliferation, influencing synaptic functions, and promoting the survival of neurons. The main drivers for the neurotrophins market are the growing focus and trials on using novel regenerative therapeutics and minimally invasive approaches.

• For instance, in March 2022, according to an article published by NCBI (National Center for Biotechnology Information), neurotrophins, specifically BDNF (Brain Derived Neurotrophic Factor) and NGF (Nerve Growth factor), administered directly and indirectly have a growing role in increasing neurogenesis and functional recovery after stroke and TBI (traumatic brain injury) and that BDNF and NGF have a synergistic role in motor learning and cognitive recovery.

Moreover, an increase in the prevalence of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, growing public awareness of the harmful implications, breakthroughs in regenerative therapeutics, and the emergence of rare diseases are the key factors driving the neurotrophin market.

• For instance, according to a report by the Alzheimer's Association, an estimated 6.5 million Americans age 65 and older are living with Alzheimer's in 2022, and 12.7 million people are projected to have Alzheimer’s dementia by 2050.


• In January 2022, according to an article published by BioMed Central Ltd, the number of cases of dementia in the developed world is projected to rise from 13.5 million in 2000 to 21.2 million in 2025 and to 36.7 million in 2050.

Impact of Covid-19 on the Neurotrophins Market

COVID-19 negatively impacted the neurotrophins market in 2020 owing to the imposed lockdowns and the worldwide compelled social isolation by the World Health Organization. Moreover, shifted focus toward treating COVID-19 patients worldwide and halting other clinical trials negatively impacted the market.

• In May 2020, According to the report published by Elsevier Inc., thousands of clinical trials were suspended or stopped because of the difficulties in continuing under lockdown conditions.

Additionally, during the pandemic, key players faced delays in getting approvals from regulatory bodies for developing the neurotrophic drug for neurodegenerative diseases.

• For instance, in December 2022, according to an article published by Athira Pharma, Inc., regulatory agencies caused delays in reviewing, commenting on or approving any of Athira’s clinical development plans as a result of the COVID-19 pandemic, and also the company was not able to recruit sufficient patients for its clinical trials, which further delayed the development timelines.

Key Insights

• Prevalence of Key Diseases, By Key Countries/Region.


• Technological advancements in Neurotrophins.


• Key Industry Developments Mergers, Acquisitions, and Collaborations.


• Impact of COVID-19 on the Neurotrophins market.

Analysis by Type

In 2022, the BDNF (Brain Derived Neurotrophic Factor) segment is the prominently growing segment of the hereditary testing market. Major players are increasing their focus on new developments and commercial strategies to strengthen their position in the market. Furthermore, the increasing number of research and clinical trials for using BDNF (Brain Derived Neurotrophic Factor) to treat Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases is expected to drive the market in the forecast period.

• For instance, in February 2020, according to a study published by MDPI (Molecular Diversity Preservation International) showed that the administration of BDNF (Brain Derived Neurotrophic Factor) increased the survival of neuronal-nuclei-stained neuronal cells and dopaminergic neurons in substantia nigra (SN), a part of the brain. Moreover, BDNF administration increased dopamine levels in patients and restored dopamine uptake, further assisting as a therapeutic agent in Parkinson’s disease.

Regional Analysis

To gain extensive insights into the market, Request for Customization

North America accounts for a large share of the global neurotrophins market due to the rising incidences of neurodegenerative diseases and the increasing number of clinical trials for treating Alzheimer’s disease and other neurodegenerative disorders in the region, anticipated to drive the market in North America during the forecast period.

• For instance, according to an article published by Alzheimer's Association in May 2021, the development of drugs used in treating Alzheimer's disease, 37.0% of phase 3 clinical trials, 60.0% of phase 2 clinical trials and 63.0% of phase 1 clinical trials for Alzheimer’s disease are conducted in North America.

Additionally, the increasing prevalence of aged population suffering from Alzheimer’s disease is expected to drive the adoption of neurotrophins for the treatment and clinical trials in the region during the forecast period.

• For instance, in September 2022, according to a study published by Case Western Reserve University,  U.S., more than 6.0 million patients aged 65 and above, show a substantially 50.0%-80.0% higher risk of developing Alzheimer's within a year.

Key Players Covered

The report will include the profiles of key players such as PeproTech, Inc., Prospec-Tany Technogene Ltd., ROCKLAND IMMUNOCHEMICALS, INC., ACROBiosystems, Merck KGaA, R&D Systems Inc, HERANTIS PHARMA Plc., BRIM Biotechnology, Inc., and others.

Segmentation

Key Industry Developments

• October 2021: Nanoform Finland Oyj, and HERANTIS PHARMA Plc., focused on disease-modifying therapies for neurodegenerative diseases based on the natural body protein CDNF (Cerebral Dopamine Neurotrophic Factor), announced results from the Nanoform Proof of Concept (PoC) project, showing that the nano forming process has been successfully applied to Herantis’ rhCDNF drug candidate. The aim was to assess the potential of Nanoform’s platform technology to improve the administration of rhCDNF via a minimally invasive intranasal spray route.


• February 2020: Merck KGaA launched the SMC (single molecule counting) Human Brain-Derived Neurotrophic Factor (BDNF) High Sensitivity Immunoassay Kit, containing all reagents used for the research process in Alzheimer’s disease.